Sales reps' presence tied to heart stent use
NEW YORK (Reuters Health) - Having sales representatives from medical device companies at hospitals may influence which products doctors use and ultimately drive up costs, according to a new study from Canada. Researchers found that doctors were more likely to use a company's drug-coated heart stent when one of its sales representatives visited their hospital, which resulted in about a $250 higher bill per case. "We need to evaluate carefully any interactions with medical industry to ensure that we minimize an effect on our decision making process," wrote Dr. Shahar Lavi, the study's lead author, in an email to Reuters Health.
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Top-Ranked MA Plans Earn Their Stars
- How Telehealth Pays Off for Providers, Patients
- House Calls Key to Pioneer ACO Success
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- Defensive Medicine Still Prevalent Despite Tort Reform
- Ebola: Health Officials Try to Quell Front Line Fears
- How Hospitals Can Become 'Upstreamists'
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening
- 4 Tips for Managing Employed Physicians